Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia

Inclusion Criteria: Blood uric acid level>7.0mg/dL (420 μmol/L) The participants did not experience any acute gout attacks before treatment The ECG of the participants was normal before treatment Exclusion Criteria: Secondary Hyperuricemia caused by kidney disease, blood disease, or taking certain drugs, tumor radiotherapy and chemotherapy, organ transplantation, etc Those who have used allopurinol, probenecid, benzbromarone, febuxostat or traditional Chinese medicine with uric acid lowering effect within 4 weeks before enrollment Those who had a history of cardiovascular and cerebrovascular diseases such as stroke, TIA, MI, HF (NYHA grade II-IV), and coronary artery surgery (such as angioplasty, stent implantation, bypass grafting, etc.) Those who had a history of gastrointestinal ulcers or gastrointestinal bleeding Active liver disease or abnormal liver function, ALT and AST are more than 3 times the upper limit of normal Glomerular filtration rate (eGFR)<30mL/min/1.73m2 Those who are allergic or intolerant to any component in Kui-Yuan chewable tablets and placebo Those who had other autoimmune diseases Those who are taking or need to take aspirin, other salicylic acids, heparin, Dicoumarol and other anticoagulants and antiplatelet aggregation drugs Those who taking Diuretic Those who had a history of alcohol or drug dependence, or those who require long-term daily use of painkillers for any reason Pregnancy, lactation, or planned pregnancy within 3 months after the last study medication